Immunoinformatics-Based Design of a Chimeric Vaccine Against Necator americanus Targeting the Na-APR-1, Na-GST-1, and Na-ASP-2 Vaccine Candidates
Hookworm infection, caused predominantly by Necator americanus, is a soil-transmitted helminthiasis that disproportionately affects impoverished communities across tropical and subtropical regions, with an estimated 406-480 million people infected globally. Control continues to rely largely on mass drug administration, an approach challenged by rapid reinfection, the absence of durable protective…
Hookworm infection, a soil-transmitted helminthiasis affecting millions worldwide, poses a significant health burden in impoverished communities of tropical and subtropical regions. Current control efforts primarily rely on mass drug administration, which struggles with reinfection, lack of durable immunity, and diminishing drug efficacy.
Among the leading protein antigens, Na-APR-1, Na-GST-1, and Na-ASP-2 have exhibited safety and immunogenicity, but the discontinuation of Na-ASP-2 due to allergic reactions highlights the need for a more comprehensive multi-antigen vaccine approach. Utilizing an immunoinformatics strategy, researchers have designed a novel chimeric vaccine candidate by strategically combining B-cell and T-cell epitopes from the major clinical-stage hookworm protein antigens with an immunostimulatory adjuvant sequence.
This candidate's three-dimensional structure was predicted, refined, and validated using established bioinformatics techniques, and its interaction with the innate immune receptor TLR4 was examined through molecular docking and normal-mode analyses. Crucially, the selected antigens demonstrated cross-species conservation, suggesting the potential for broader protective effects.
Laboratory simulations revealed the candidate's capacity to trigger both humoral and cellular immune responses while being antigenic, non-allergenic, and non-toxic. Population coverage analysis further indicated its broad applicability. Docking and normal-mode analyses confirmed the vaccine's stable and favorable interaction with TLR4.
This research represents a rational, safety-oriented strategy for designing multi-epitope vaccines against hookworm infection, building upon clinically validated protein antigens while mitigating the safety concerns inherent in previous single-antigen candidates. However, further experimental validation, both in vitro and in vivo, is necessary to ascertain the vaccine's safety and efficacy.
These findings pave the way for future endeavors aimed at developing an effective immunoprophylactic strategy against this neglected disease.
Written by urgent.news from bioRxiv's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
